15 unchanged sentences
On October 30, 2013, our Board approved an equity repurchase program (the “Repurchase Program”) authorizing the repurchase of up to $125 million of our common stock.
−Removed: Our Board increased the stock repurchase authorization under the Repurchase Program with respect to the repurchase of our common stock by $600 million, $1.5 billion, $2.0 billion, $1.5 billion, $2.0 billion, and $2.0 billion in 2015, 2016, 2017, 2018, 2019, and 2022, respectively.
−Removed: On July 31, 2023, our Board increased the stock repurchase authorization under the Repurchase Program by an addition al $2,000 million, which increased the total amount that has been authorized under the Repurchase Program to $11,725 million.
+Added: Our Board increased the stock repurchase authorization under the Repurchase Program with respect to the repurchase of our common stock by $600 million, $1.5 billion, $2.0 billion, $1.5 billion, $2.0 billion, $2.0 billion, and $2.0 billion in 2015, 2016, 2017, 2018, 2019, 2022, and 2023, respectively.
+Added: On February 5, 2025, the Board increased the stock repurchase authorization under the Repurchase Program with respect to the repurchase of the Company's common stock by an additional $2,000 million, which increased the total amount that has been authorized under the Repurchase Program to $13,725 million.
The Repurchase Program does not obligate us to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time.
4 unchanged sentences
From inception of the Repurchase Program through December 31, 2024, we have repurchased a total of $10,712 million of our securities under the Repurchase Program.
−Removed: During the year ended December 31, 2023, we repurchased 5.0 million shares of our common stock for approximately $992 million under the Repurchase Program.
+Added: During the year ended December 31, 2024, we repurchased 6.4 million shares of our common stock for $1,350 million under the Repurchase Program.
For additional information regarding our equity repurchases, see Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” and Note 13 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
−Removed: As of December 31, 2023, we had remaining authorization to repurchase up to approximately $2,363 million of our common stock under the Repurchase Program.
+Added: As of December 31, 2024, we had remaining authorization to repurchase up to $1,013 million of our common stock under the Repurchase Program.
Since the Merger between Quintiles and IMS Health in October 2016, we have repurchased 84.6 million shares of our common stock at an average market price per share of $122.23 for an aggregate purchase price of $10,338 million both under and outside of the Repurchase Program.
16 unchanged sentences
under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
−Removed: The following graph shows a comparison from December 31, 2018 through December 31, 2023 of the cumulative total return for our common stock, the Standard & Poor’s 500 Stock Index (“S&P 500”), our new peer group set forth below ("New Peer Group"), and our old peer group set forth below ("Old Peer Group").
−Removed: The New Peer Group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc.
−Removed: The difference between the New Peer Group and the Old Peer Group is that Laboratory Corporation of America Holdings, Syneos Health, Equifax Inc., Thomson Reuters Corporation and Verisk Analytics, Inc.
−Removed: have been removed from the New Peer Group as these companies were either spun-off, acquired by a private equity consortium or not relevant anymore during the year ended December 31, 2023.
−Removed: Simultaneously, Fortrea Holdings Inc., Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc.
−Removed: were added to the New Peer Group during the year ended December 31, 2023.
−Removed: The companies in our peer groups are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar customers as IQVIA.
+Added: The following graph shows a comparison from December 31, 2019 through December 31, 2024 of the cumulative total return for our common stock, the Standard & Poor’s 500 Stock Index (“S&P 500”), and our peer group set forth below.
+Added: The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc.
+Added: The companies in our peer group are publicly traded information services, information technology or clinical research companies, and thus share similar business model characteristics to IQVIA, or provide services to similar customers as IQVIA.
Many of these companies are also used by our compensation committee for purposes of compensation benchmarking.
−Removed: The graph assumes that $100 was invested in IQVIA, the S&P 500, the New Peer Group, and the Old Peer Group as of the close of market on December 31, 2018, and assumes the reinvestments of dividends, if any.
−Removed: The S&P 500 and our New and Old Peer Groups are included for comparative purposes only.
−Removed: They do not necessarily reflect management’s opinion that the S&P 500 and our peer groups are an appropriate measure of the relative performance of the stock involved, and they are not intended to forecast or be indicative of possible future performance of our common stock.
+Added: The graph assumes that $100 was invested in IQVIA, the S&P 500, and our peer group as of the close of market on December 31, 2019, and assumes the reinvestments of dividends, if any.
+Added: The S&P 500 and our peer group are included for comparative purposes only.
+Added: They do not necessarily reflect management’s opinion that the S&P 500 and our peer group are an appropriate measure of the relative performance of the stock involved, and they are not intended to forecast or be indicative of possible future performance of our common stock.
12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
1 unchanged sentence
$ 100 $ 118 $ 152 $ 125 $ 158 $ 197
−Removed: New Peer Group $ 100 $ 150 $ 209 $ 305 $ 241 $ 257
−Removed: Old Peer Group $ 100 $ 143 $ 183 $ 261 $ 196 $ 256
+Added: Peer Group $ 100 $ 140 $ 204 $ 161 $ 172 $ 174
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.